ClinicalTrials.gg
CompletedNCT07597473Updated Nov 3, 2026

Dymista in Chinese Adolescents

A Phase 4 interventional study of Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate in Allergic Rhinitis Due to Allergens, sponsored by Viatris Inc.. Completed at 14 sites in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Viatris Inc. · Phase 4, Interventional, and Treatment

Updated Nov 3, 2026Now CompletedNow Active, not recruiting+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Rhinitis, Allergic with a site in China — 32 open to participants now, 34 under way, 2 of them phase 3. Rhinitis, Allergic · China.

Enrollment
28th of 67
100 · median 93
Started
2026
with 6 others
Phase 4
9 of 82
none open now
Registered
77th of 82
by date

Among the 82 studies in Rhinitis, Allergic with a site in China, this one is the 28th largest by enrollment of the 67 interventional ones that give a count, is one of 7 that started in 2026, is one of 9 in phase 4, and was the 77th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

32 of the 82 studies in Rhinitis, Allergic with a site in China are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Rhinitis, Allergic with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the investigational drug product ("study drug"), Dymista (azelastine hydrochloride and fluticasone propionate) nasal spray is safe and effective in the treatment of allergic rhinitis in Chinese adolescents with or without ocular symptoms.

It is expected that approximately, 100 participants will be enrolled in this study. The study will be performed in approximately 15 clinical study centers in China.

Study participants will be asked to complete up to 3 study visits at the study site and a follow-up by telephone.

Treatment Assignment:

All participants will receive a bottle of Dymista nasal spray and should administer it at a dose of twice daily (one spray per nostril), once in the morning and once in the afternoon, the doses will be approximately 12 hours apart. The liquid medicine is sprayed out in a mist after actuator is pressed. You will administer the trial intervention for 14 (+5) days.

Regular study schedule:

  • Screening visit (Visit 1, Day -7 to 1)
  • Baseline visit (Visit 2, Day 1)
  • Visits 3 (End of Trial (EOS), Day 15 (+5))
  • Follow-up (Telephone Call, within 14 (+5) days after the last administration of Dymista) The participation may last approximately 29 days to 60 days (depending on extended periods of screening, treatment, and follow-up).
Read the detailed description

Trial Design and Rationale for Trial Design:

This is a multicenter, phase 4, single arm clinical trial to evaluate the efficacy and safety of Dymista nasal spray (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in the treatment of AR in Chinese adolescents with or without ocular symptoms. Because Dymista has already been approved, this trial design is selected to gather additional data on efficacy and safety of Dymista in Chinese adolescents in a close to real-world setting but under clinical oversight.

Number of Participants: Approximately 100 participants will be enrolled into the study.

Number of Arms: Single arm

Duration: Total duration of trial participation for each participant will vary from 29 to 60 days (depending on extended periods of screening, treatment, and follow-up).

This trial starts with approximately -7 to 1 day of screening period, i.e., Visit 2 (start of treatment) can eventually be on the same day of Visit 1 or up to 7 days later. Treatment period will be for 2 weeks (14+5 days) during which participants will administer Dymista nasal spray (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in each nostril, twice daily (BID) and then return to the study site at Visit 3 for end of study examination on Day 15 (+5). Subsequently, participants will be followed up for any AEs for 2 weeks (14+5 days) after the last dose via phone. Once an AE is detected and ongoing, it should be followed up at least two weeks later (i.e., 28 (+5) days after last dose) until its resolution or until it is judged by the principal investigator to be stable or permanent.

Blinding: Not Applicable (No blinding).

Main Selection Criteria - Inclusion and Exclusion criteria of Trial Population:

The Inclusion Criteria for the study focus on enrolling Chinese participants aged 12-17 years who have moderate-to-severe seasonal and/or perennial AR, with or without ocular symptoms. Participants must show signs of Immunoglobulin E (IgE)-mediated hypersensitivity confirmed by diagnostic tests, have acute allergic rhinitis symptoms at inclusion, and be in general good health. They must also be able to use Dymista nasal spray correctly, agree to complete study requirements such as the patient diary, and provide informed consent/assent along with their legal guardians.

The Exclusion Criteria aim to ensure participant safety and study integrity. Individuals with known allergies to Dymista or its components, pregnant or breastfeeding females, or those unable to comply with study requirements are excluded. Additional exclusions include nasal conditions that interfere with drug delivery, recent nasal or sinus surgery, chronic sinusitis, recent use of investigational drugs or certain medications, respiratory infections, asthma (except mild intermittent), and recent immunotherapy. Individuals anticipating significant environmental changes are also excluded.

Trial Treatment:

Dymista nasal spray (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate, administered twice daily)

03

Conditions studied

  • Allergic Rhinitis Due to Allergens

Browse trials for

Keywords

  • Allergic Rhinitis
  • Azelastine hydrochloride
  • Fluticasone propionate
  • Nasal spray
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Chinese participants aged 12 to 17 years (inclusive) at screening.
  • /assent from participants and from parent(s) or legal guardian(s) in compliance with local requirements.
  • Participants must have moderate-to-severe seasonal and/or perennial AR with or without ocular symptoms, defined as rhinitis with one or more of the following being present:

    • Sleep disturbance
    • Impairment of daily activities, leisure, and/or sport
    • Impairment of learning or work
    • Troublesome symptoms
  • Moderate to severe seasonal and/or perennial AR with or without ocular symptoms in whom intranasal antihistamines or monotherapy is not considered sufficient at the discretion of the Investigator and/or designee.
  • Presence of Immunoglobulin E (IgE)-mediated to one or more aeroallergens present in the current participant environment, confirmed by a positive response to an established standard diagnostic test at the site within the last year (before treatment start). Accepted diagnostic tests include:

    • Skin prick tests
    • Specific IgE tests Diagnosis of hypersensitivity will follow the current clinical practice at study sites.
  • Acute allergic rhinitis symptoms at the day of inclusion evidenced by a 12-hour reflective TNSS ≥8 out of 12.
  • General good health and free of any disease or concomitant treatment that may increase the risk associated with study participation or product administration or could interfere with the interpretation of the study results as determined by the Investigator or the Sponsor's medical officer. When in doubt, the Investigator should confer with the Sponsor's medical monitor or designee to determine eligibility for the study.
  • Negative pregnancy test in females with .
  • Ability to understand and follow the instructions for using Dymista nasal spray according to the participant information leaflet.
  • Willingness to complete and return the Patient Diary and comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

Safety concerns:

  • Known allergic reaction from and/or intolerance to Dymista, azelastine hydrochloride, fluticasone propionate nasal sprays or any of the ingredients
  • Pregnancy/planned pregnancy or breastfeeding during this study

Lack of suitability for the study:

  • Participants or parent(s)/legal guardian(s) are not able to fulfil study requirements according to Investigator's opinion.
  • nasal or sinus disease that may affect intranasal drug deposition, including but not limited to nasal mucosal erosion/ulceration or septum perforation (Grade 1b - 4), significant polyposis, marked septum deviation, active or recurrent sinusitis (>3 episodes/year), or nasal/sinus surgery within the past 12 months.
  • The use of any drug within 30 days or within 5 half-lives of the investigational drug (whichever is longer) prior to inclusion. No other investigational products are permitted for use during the conduct of this study.
  • Respiratory tract infections within 7 days prior to inclusion.
  • Asthma (with the exception of mild intermittent asthma). Participants with mild intermittent asthma who only require short-acting inhaled bronchodilators and who do not have nocturnal awakening as a result of asthma are eligible for enrolment.
  • Current use or expected requirement of ritonavir or strong P4503A4 inhibitors including cobicistat-containing products.
  • Specific immunotherapy within 6 months prior to Screening Visit. If the participant received immunotherapy a 6-month is required following the last dose of immunotherapy.
  • Use of the following medications or therapies within the time period specified below prior to Screening Visit:

Medication/Therapy Time Prior to Screening Visit

  • Antihistamines: including oral, ocular, intranasal, prescribed and over the counter, biological active supplements, cold preparation, sleep aids containing such components (5 days)
  • Oral and intranasal anticholinergic agents including ipratropium nasal spray (5 days)
  • Inhaled, oral (30 days)
  • Intranasal corticosteroids (14 days)
  • Systemic steroids, includes oral, injected, intravenous [IV], (30 days)
  • Ocular corticosteroids (7 days)
  • Leukotriene inhibitors (14 days)
  • Oral antibiotics for Respiratory tract infections (14 days)
  • Cromolyn compounds, all mast cell stabilizers (14 days)
  • Ephedrine or pseudoephedrine containing products (5 days)
  • Decongestants including cold preparations (5 days)
  • Traditional Chinese Medicines (TCM) for treatment of AR with known active ingredient, e.g. antihistamines, ephedrine or pseudoephedrine, (5 days)
  • TCM for treatment of AR with unknown active ingredient (14 days)
  • Tricyclic antidepressants (30 days)
  • Monoamine oxidase inhibitors (14 days)
  • Immunosuppressives/immunomodulators, e.g., anti-tumour necrosis factor (TNF) agents (30 days)
  • IgE antagonist or other biologics (130 days)

Administrative reasons:

- Participants anticipating significant changes in their daily environmental exposure (e.g. travel more than 3 days).

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Treatment with intranasal spray of Dymista

    The study drug will be delivered as an intranasal spray of Dymista (137 μg of azelastine hydrochloride and 50 μg of fluticasone propionate) in each nostril, BID, approximately 12 hours apart at AM and PM. The formulation is a white suspension which contains 120 sprays per bottle. The liquid medicine is sprayed out in a mist after actuator is pressed.

    Drug: Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate

Interventions

  • DrugTreatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate

    Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate twice daily in each nostril for 14 days

06

What researchers measure

Primary outcomes

  1. Change from baseline in AM+PM combined reflective Total Nasal Symptom Score (rTNSS).

    Least Sqares (LS) mean change from baseline over 14 days (Day 2 to Day 14) in AM+PM combined rTNSS after treatment with Dymista nasal spray regardless of discontinuation for any reason or low compliance (treatment policy strategy). Explanation of rTNSS scale and score: The reflective Total Nasal Symptom Score (TNSS) evaluates nasal symptoms associated with AR. It includes four nasal symptoms: nasal itching, nasal congestion, runny nose (rhinorrhea) and sneezing. The symptom severity is scored on a four-point scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The severity of each symptom is assessed to arrive at the total TNSS score, which ranges from 0 to 12. Hence, the AM + PM combined TNSS ranges from 0 to 24.

    Time frame: From enrollment to end of treatment at 2 weeks.

Secondary outcomes

  1. Changes from baseline in AM+PM combined reflective TOSS

    The secondary objective is to evaluate efficacy in relief of further Allergic Rhinitis (AR) associated symptoms of Dymista in Chinese adolescents, having moderate to severe seasonal and/or perennial AR with or without ocular symptoms. Explanation of TOSS scale and scores: The reflective Total Ocular Symptom Score (TOSS) evaluates ocular symptoms associated with AR. It includes three symptoms: itchy eyes, watery eyes, and eye redness. The symptom severity is scored on a fourpoint scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The severity of each symptom is assessed to arrive at the total TOSS score, which ranges from 0 to 9. Hence, the AM + PM combined TOSS ranges from 0 to 18.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  2. Changes from baseline in AM+PM combined reflective T7SS

    The secondary objective is to evaluate efficacy in relief of further Allergic Rhinitis (AR) associated symptoms of Dymista in Chinese adolescents, having moderate to severe seasonal and/or perennial AR with or without ocular symptoms. Explanation of T7SS scale and scores: The reflective Total 7 Symptom Score (T7SS) evaluates the combined nasal and ocular symptoms (reflective Total Nasal Symptom Score + reflective Total Ocular Symptom Score) associated with AR. It includes all seven symptoms from rTNSS and rTOSS combined: nasal itching, nasal congestion, runny nose (rhinorrhea), sneezing, itchy eyes, watery eyes, and eye redness. The symptom severity is scored on a four-point scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The severity of each symptom is assessed to arrive at the total rT7SS score, which ranges from 0 to 21. Hence, the AM + PM combined T7SS ranges from 0 to 42.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  3. Changes from baseline in individual nasal symptom scores (itchy nose, nasal congestion, runny nose, sneezing) and ocular symptom scores (itchy eyes, watery eyes, eye redness)

    The secondary objective is to evaluate efficacy in relief of further Allergic Rhinitis (AR) associated symptoms of Dymista in Chinese adolescents, having moderate to severe seasonal and/or perennial AR with or without ocular symptoms. The symptom severity is scored on a four-point scale \[0-3\] for each symptom, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. Hence, each AM + PM combined individual symptom score ranges from 0 to 6.

    Time frame: From enrollment to the end of treatment at 2 weeks.

Other outcomes

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participants or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory or physical findings, symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. TEAE is defined as AE with onset date/time since the first dosing of study medication until 120 hours after the last dose of study medication.

    Time frame: From enrollment to 14 days after the last dose.

07

Study locations

14 sites
  • Capital Center for Children's Health, Capital Medical University
    Beijing, China
  • Hunan Provincial People's Hospital
    Changsha, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • Dalian Municipal Central Hospital
    Dalian, China
  • Affiliated Hangzhou First people's hospital, School of Medicine, Westlake University
    Hangzhou, China
  • Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, China
  • Eye & Ent Hospital of Fudan University
    Shanghai, China
  • The Second Affiliated Hospital of Shanxi Medical University
    Taiyuan, China
  • Tianjin Union Medical Center/Nankai University Affiliated Hospital
    Tianjin, China
  • The Central Hospital of Wuhan
    Wuhan, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, China
  • The Second Affiliated Hospital of Xi'an JiaotongUniversity(XibeiHospital)
    Xi'an, China
  • Central Hospital of Zibo
    Zibo, China
08

References and documents

Individual participant data

Plan to share: No — Company procedures to share IPD are under development. If procedures are established during the course of the study, the plan will be described.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Sep 2026, 4 months.

Of 34 phase 4 interventional studies under Rhinitis, Allergic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 38. This study's 4 months is below that.

Primary completion moved twice since we started tracking on Sep 25, 2026: Mar 2027 → Sep 2026, last on Nov 3, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Oct 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 19, 2026
StartActual
May 8, 2026
Primary completionActual
Sep 19, 2026was Mar 2027
CompletionActual
Oct 13, 2026was Mar 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Sep 29, 2026 · changed Nov 3, 2026
Sites
1 site removed
Show 1 removed
  • The Third XiangyaHospital of Central South University · Changsha, China
Sep 29, 2026
Primary completion
Mar 2027→Sep 19, 2026 (actual)
moved 2 times, Sep 29, 2026 – Nov 3, 2026
Study completion
Mar 2027→Oct 2026
Sep 29, 2026
Show all 2 updates
  1. Nov 3, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2026→Sep 19, 2026 (now actual)
    + 1 other change: verification date
  2. Sep 29, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • The Third XiangyaHospital of Central South University · Changsha, China
    Primary completion Mar 2027→Oct 2026
    Study completion Mar 2027→Oct 2026
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07597473
Lead sponsor
Viatris Inc.
Responsible party
Sponsor
First posted
May 19, 2026
Start date
May 8, 2026
Primary completion
Sep 19, 2026
Completion
Oct 13, 2026
Last update
Nov 3, 2026

Study contacts

Duc Tung Nguyen, Dr.
study director · MEDA Pharma GmbH & Co. KG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion